Lineage Cell Therapeutics (LCTX) Cash from Operations Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 356.73% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -65.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.33% |
| Dec 31, 2025 | 23.13% |
| Sep 30, 2025 | 37.52% |
| Jun 30, 2025 | -7.01% |
| Mar 31, 2025 | 15.51% |
| Dec 31, 2024 | -5.43% |
| Sep 30, 2024 | -14.89% |
| Jun 30, 2024 | 17.42% |
| Mar 31, 2024 | 48.56% |
| Dec 31, 2023 | 27.51% |
| Sep 30, 2023 | 8.08% |
| Jun 30, 2023 | 11.24% |
| Mar 31, 2023 | -151.32% |
| Dec 31, 2022 | -41.38% |
| Sep 30, 2022 | -13.04% |
| Jun 30, 2022 | -30.39% |
| Mar 31, 2022 | 395.04% |
| Dec 31, 2021 | -4.11% |
| Sep 30, 2021 | -0.02% |
| Jun 30, 2021 | -27.77% |